## **Supporting Information**

## Meng et al. 10.1073/pnas.1722013115



**Fig. S1.** Effect of hRIPK1 K599R mutation on RIPK1 dimerization and cell death. (*A*) HEK293T cells were cotransfected with expression vectors of Myc-tagged full-length RIPK1, Flag-RIPK1-DD, and Flag-RIPK1-DD-K599R as indicated for 24 h, the cells were then lysed with 0.5% Nonidet P-40 buffer, and cell lysates were immunoprecipitated with anti-Myc antibody-conjugated agarose. (*B*) RIPK1-deficient Jurkat cells were infected with retrovirus encoding Flag-tagged hRIPK1 WT and Flag-tagged hRIPK1 K599R by the Tet-On Advanced Inducible Expression System. Different RIPK1-reconstituted Jurkat cells were treated with 1  $\mu$ g/mL doxycycline for 48 h to induce the expression of RIPK1. The cells were then pretreated with 100 nM SM-164, 100 nM 5Z-7, or CHX 1  $\mu$ g/mL for 2 h and treated with 100 ng/mL TNFa and 50  $\mu$ M zVAD.fmk for 10 h. The cell survival was measured by CellTiterGlo. Results shown are averages of triplicates  $\pm$  SEM (\*\**P* < 0.01; \*\*\*\**P* < 0.0001). (*Right*) Western blot analysis of RIPK1 expression levels in RIPK1-deficient Jurkat cells infected with retrovirus encoding Flag-tagged hRIPK1 WT and K599R. (C) Sequence alignment of the death domains of human and murine RIPK1 around the K599/K584 region. K599/K584 residues conserved in humans and mice are highlighted in gray.



**Fig. S2.** Ripk1<sup>K584R</sup> cells are resistant to RIPK1-dependent cell death but not RIPK1-independent apoptosis. (*A*) A schematic diagram of the murine *Ripk1* locus and the *Ripk1* K584R allele. (*B*) Numbers of surviving offspring from mating of *Ripk1<sup>K584R/+</sup>* parents. (C) WT, *Ripk1<sup>K584R/+</sup>*, and *Ripk<sup>K584R/+</sup>* immortalized MEFs were pretreated with 25 nM SM-164 (*Left*) or 100 nM 5Z-7 (*Middle*) for 2 h and then treated with 50  $\mu$ M zVAD.fmk or treated with 20 ng/mL TNF $\alpha$  and 50  $\mu$ M zVAD.fmk (*Right*) as indicated for different time points. (*D* and *E*) WT, *Ripk1<sup>K584R/+</sup>*, and *Ripk<sup>K584R/+</sup>* immortalized MEFs were treated with TNF $\alpha$ +CHX to induce apoptosis (*D*) or treated with TNF $\alpha$ +CHX+zVAD.fmk to induce necroptosis (*E*). The cell survival was measured by CellTiterGlo (*A*–C). (\**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001; \*\*\*\**P* < 0.001.) (*F*) WT and *Ripk<sup>K584R/K584R/K584R</sup>* immortalized MEFs were treated with 0.5% Nonidet P-40 buffer and analyzed by Western blotting with caspase and PARP cleavage to indicate apoptosis.



**Fig. S3.** The *Ripk1<sup>KS84R</sup>* mutation disrupts the formation of complex II. (*A* and *B*) Primary WT, *Ripk1<sup>KS84R/+</sup>*, and *Ripk<sup>KS84R/KS84R</sup>* MEFs were pretreated with SM-164 ± zVAD (*A*) or 5Z-7 ± zVAD (*B*) for 1 h as indicated, and then Flag-TNFα was added for 5 min, cells were then lysed with 0.5% Nonidet P-40 buffer, and cell lysates were immunoprecipitated with anti-Flag antibody-conjugated agarose. All immunoprecipitated proteins and whole-cell lysates were analyzed by Western blotting with indicated antibodies. (*C*) RIPK1-deficient Jurkat cells infected with retrovirus encoding HA-tagged WT or K599R hRIPK1 were treated with Flag-TNFα for the indicated time. The cells were then lysed with 0.5% Nonidet P-40 buffer and immunoprecipitated with anti-Flag antibody-conjugated agarose. (*D*) Primary WT and *Ripk1<sup>K584R/K584R</sup>* MEFs were treated with TNFα and then lysed with 0.5% Nonidet P-40 buffer and immunoprecipitated with anti-Flag antibody-conjugated agarose. (*D*) Primary WT and *Ripk1<sup>K584R/K584R</sup>* MEFs were treated with TNFα and then lysed with 0.5% Nonidet P-40 buffer and immunoprecipitated with anti-Flag antibody-conjugated agarose. (*D*) Primary WT and *Ripk1<sup>K584R/K584R</sup>* MEFs were treated with TNFα and then lysed with 0.5% Nonidet P-40 buffer and immunoprecipitated with anti-Flag antibody-conjugated agarose. (*D*) Primary WT and *Ripk1<sup>K584R/K584R</sup>* MEFs were treated with TNFα and then lysed with 0.5% Nonidet P-40 buffer and immunoprecipitated with anti-Flag antibody-conjugated agarose. (*D*) Primary WT and *Ripk1<sup>K584R/K584R</sup>* MEFs were treated with NFα and actin as indicated. (*F*) Immortalized MEFs were pretreated with CHX, SM-164, or 52-7 for 2 h and then treated with TNFα as indicated at different time points. The cells were lysed with 0.5% Nonidet P-40 buffer and immunoprecipitated with anti-FADD antibody. The immunoprecipitated complexes and whole-cell lysates were analyzed by Western blotting with RIPK1.



**Fig. 54.** The RIPK1 K584R mutation does not directly inhibit RIPK1 kinase activity or affect protein stability. (*A*) The RIPK1 KO 293T cells were transfected with HA-tagged RIPK1 WT or K599R expression plasmids in the presence or absence of 10  $\mu$ M Nec-1s. The cell lysates were collected 24 h after transfection and analyzed by Western blotting with the indicated antibodies. (*B* and C) The melting temperature (Tm) (*B*) and thermal stability profiles (C) of WT and K599R hRIPK1-DD. hRIPK1 (583-671AA) was purified from the *E. coli* expression system following overnight induction at 4 °C. hRIPK1-DD WT and K599R (4  $\mu$ M, 6  $\mu$ M) protein thermal stability were analyzed through the use of differential scanning calorimetry by real-time PCR and the melting temperatures were calculated by Protein Thermal Shift Software. Four replicates for each reaction were performed. (*D* and *E*) WT and *Ripk1<sup>K584R/K584R</sup>* (*D*) and WT *and Ripk1<sup>D138/LD138/N</sup>* (*E*) immortalized MEFs were pretreated with 5Z-7 for 2 h and then treated with TNFx for the indicated time. The cells were lysed with 0.5% Nonidet P-40 buffer and analyzed by Western blotting analysis using p-S166 RIPK1 and RIPK1 antibodies.